Kevin Sheth

Kevin Sheth, MD, is the Chief Medical Adviser at Astrocyte Pharmaceuticals, where he plays a pivotal role in advancing therapies for acute brain injuries such as stroke and traumatic brain injury (TBI). He is also a critical care neurologist at Yale Medicine and the founding Director of the Yale Center for Brain & Mind Health. His work focuses on developing innovative strategies for treating conditions complicated by brain swelling and hemorrhage, significantly impacting clinical practices in neurocritical care.12

Professional Background

• Education: Dr. Sheth graduated from Johns Hopkins University and earned his medical degree from the University of Pennsylvania School of Medicine.
• Career: He completed his internship at Brigham and Women's Hospital and his neurology residency at Partners Neurology. In 2013, he was recruited to Yale as the chief of the Division of Neurocritical Care and Emergency Neurology.1
• Research Contributions: Dr. Sheth has led numerous multicenter clinical trials and is a principal investigator for NIH neuroscience networks. He has authored over 300 publications and received several prestigious awards for his contributions to neurology.12

Role at Astrocyte Pharmaceuticals

As Chief Medical Adviser, Dr. Sheth is instrumental in overseeing clinical research and development initiatives. He has been involved in significant projects, including the upcoming Phase 2 clinical trial for AST-004, a novel therapy aimed at reducing brain damage in stroke patients.23 His collaborations with pharmaceutical companies have enhanced the understanding and treatment of neurological diseases through innovative drug delivery methods and neuroimaging technologies.12

Recognition

Dr. Sheth has received multiple accolades, including the Robert Siekert Award from the American Heart Association and the Derek Denny Brown Award from the American Neurological Association, highlighting his impact on stroke research and clinical practice.1